NasdaqGS:MRNABiotechs
Moderna (MRNA) Valuation Check After Upgraded 2025 Outlook And Pipeline Update At J.P. Morgan Conference
Moderna (MRNA) is back in focus after its J.P. Morgan Healthcare Conference update, where management lifted the 2025 revenue forecast to about US$1.9b, outlined lower operating expenses, and reaffirmed its 2026 growth and 2028 cash breakeven targets.
See our latest analysis for Moderna.
The revenue upgrade and cost guidance from the J.P. Morgan Healthcare Conference has come alongside a sharp shift in sentiment. Moderna’s 1 day share price return of 17.02% has fed into a 30 day return of...